These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Irinotecan in the treatment of colorectal cancer: clinical overview. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. J Clin Oncol; 2001 Mar 01; 19(5):1501-18. PubMed ID: 11230497 [Abstract] [Full Text] [Related]
4. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. J Clin Oncol; 2003 Mar 01; 21(5):807-14. PubMed ID: 12610178 [Abstract] [Full Text] [Related]
15. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. Van Cutsem E, Peeters M. Bull Cancer; 1998 Dec 13; Spec No():33-7. PubMed ID: 9932082 [Abstract] [Full Text] [Related]
16. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D. J Clin Oncol; 1995 Jan 13; 13(1):210-21. PubMed ID: 7799022 [Abstract] [Full Text] [Related]
18. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group. Comella P, Biglietto M, Casaretti R, De Lucia L, Avallone A, Maiorino L, Di Lullo L, De Cataldis G, Rivellini F, Comella G. Oncology; 2001 Jan 13; 60(2):127-33. PubMed ID: 11244327 [Abstract] [Full Text] [Related]
19. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC. Cancer Res; 1994 Jan 15; 54(2):427-36. PubMed ID: 8275479 [Abstract] [Full Text] [Related]